Get A CAL-101 With No Need Of Putting In A Single Coin

815, 95% CI: 0.697- 0.933, p 0.02 ng/ml after radiotherapy was significantly associated with increased risk of biochemical failure on univariate analysis (HR = 28.57; 95% CI: 12.04-66.66; p 0.02 ng/ml and �� 0.02 ng/ml, respectively (Figure 3A). Table 2 Predictive factors for worse biochemical control on proportional hazard model Sitaxentan Fig. 3 Kaplan-Meier estimate of (A) biochemical no evidence of disease rate and (B) prostate cancer specific-survival rate based on prostate-specific antigen nadir (nPSA) after high-dose-rate brachytherapy combined with external beam radiation therapy, respectively. ... Upon multivariate analysis, the nPSA value after radiotherapy was a significant independent predictor of biochemical failure (HR = 26.31; 95% CI: 10.00-71.42; p selleck inhibitor nPSA > 0.02 ng/ml after radiotherapy than in patients with lower nPSA values (HR = 32.25; 95% CI: 3.401-333.3; p = 0.002). The 7-year cancer specific-survival rate was 82.4% and 99.4% in patients with nPSA after radiotherapy > 0.02 ng/ml and �� 0.02 ng/ml, respectively (Figure 3B). ROC curve was performed to evaluate an optimal cut-point of time to achieve a PSA level of �� 0.02 ng/ml after radiotherapy as a predictive value for biochemical failure. With a cutoff point of 1 year, the sensitivity and specificity were 89.9% and 60%, respectively. The AUC-ROC was 0.815 (95% CI: 0.639-0.944, p Afatinib mouse reached a PSA level of �� 0.02 ng/ml during the entire follow-up period. Using this cut-off point, 196 patients who reached a PSA level of �� 0.02 ng/ml were divided into 2 groups according to how long it took to achieve that level: �� 1 year after radiotherapy (n = 171) and > 1 year after radiotherapy (n = 25). Biochemical failure rate was significantly higher in patients with PSA level of �� 0.02 achieved > 1 year after radiotherapy than in those with �� 1 year (HR = 15.38; 95% CI: 3.846-62.50; p